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Transfusion associated Graft versus Host Disease (TA-GVHD) is a well-known but rare complication that 
follows infusion of histo-incompatible lymphoid cells, often seen in individuals with impaired cellular 
immunity. However, it may also occur in immunocompetent individuals. The clinical syndrome consists of 
fever, skin rash, diarrhea, hepatic dysfunction, and bone marrow aplasia. The outcome is nearly always fatal. 
We present here a case report of fatal TA-GVHD in a “presumed” immunocompetent patient after 
transfusion of whole blood from a first and a second degree relative following orthopedic surgery for right 
coxarthrosis. 
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İMMUNKOMPETAN BİR HASTADA ORTOPEDİK CERRAHİ SONRASI GELİŞEN 




Transfüzyonla ilişkili Graft versus Host Hastalığı, genellikle hücresel immünitesi bozulmuş bireylerde 
histokompatibl olmayan lenfoid hücrelerin transfüzyonu sonrası gelişen, iyi bilinen fakat nadir bir 
komplikasyondur. İmmünitesi sağlam olan bireylerde de nadiren görülebilir. Ateş, cilt döküntüsü, diyare, 
karaciğer fonksiyon bozukluğu ve kemik iliği aplazisi bu hastalığın klinik tablosunu oluşturur. Hemen her 
zaman ölümcül seyreder. Burada, sağ koksartroz nedeniyle ortopedik cerrahi sırasında birinci ve ikinci 
derece akrabalarından kan transfüzyonu yapılan immünkompetan bir hastadaki ölümcül seyreden 
Transfüzyonla ilişkili Graft versus Host Hastalığı olgusu sunulmuştur. 
 





Many transfusion reactions are not recognized as 
such, perhaps because signs and symptoms mimic 
other clinical conditions. TA-GVHD is a rare but 
dangerous and fatal complication of blood 
transfusion. It basically affects patients with 
impaired T-cell-related immunity. However, it 
may also occur in immunocompetent individuals. 
It is mainly reported after open heart surgery and 








transfusion practice in any surgery should be 
appropriately recognized. The disease is 
characterized by fever, skin rash, liver failure and 
pancytopenia1. We present here a case report of 
fatal TA-GVHD in a “presumed” 
immunocompetent patient after transfusion of 
whole blood from a first and a second degree 
relative following orthopedic surgery for right 
coxarthrosis. 
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A 58-year-old male patient who initially presented 
with fever, macular erythematous rash and 
pancytopenia was admitted to our clinic. He had 
no complaints until 2 days before admission when 
he noticed maculopapular rash on the dorsal 
aspects of his feet and over his chest. Later on, the 
rash spread to his arms and back (Fig. 1). The day 
before admission, he developed high fever 














Fig. 1: Rash on his arms and hands 
 
He had had a right total hip replacement operation 
for coxarthrosis 3 weeks previously. After the 
operation, 3 units of nonirradiated whole blood 
(one unit from his son, one unit from his cousin 
and another  from an unrelated person) were 
transfused. His total blood count before the 
operation were within normal ranges [ White 
blood cells (WBC): 7300 / mm³, Hemoglobin 
(Hb): 14.9 mg/dL , Hematocrit (Htc): 33.8%, 
Platelets (Plt): 187000 / mm³]. He had used 
nonsteroidal anti-inflammatory drugs (ibuprofen, 
naproxen) and analgesics (paracetamol) for pain 
in the right hip joint. Cefazoline was given for 
surgical prophylaxis. Medical history of his 
family was unremarkable. 
 
On admission, his temperature was 39.5ºC,  pulse 
rate  88 / min,  respiratory rate  20 / min and  
blood pressure  120/60 mmHg. On physical 
examination, the patient seemed fatigued and 
confused, erythematous macular rash was present 
on his abdomen, back, arms and purpuric rash 
with no bleach on pressure on his legs (Fig. 2). No 
lymphadenopathy was found. Hyperemia was 
observed on the pharynx and tonsils. The tonsils 
were also hypertrophic. Enanthems were observed 
on the hard palate. No abnormal breathing sound 
or pleural friction rub was heard. Examination of 
the heart and the abdomen revealed no 
abnormalities except for  an erythematous rash on 
the abdomen. No costovertebral or suprapubic 
tenderness was detected. Both hips were mobile; 
no pain or limitation of motion was elicited. His 
hands and feet seemed edematous and 
erythematous (Figs. 3-5). Initial neurologic 





























Fig. 3: Diffuse erythema and edema of his hands and 













Fig. 4: Diffuse erythema and edema of hands 
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Fig, 5: Rash and edema of his feet 
 
Initial complete blood count revealed 
pancytopenia ( WBC: 700 /mm3, Hb: 8.5 mg/dL, 
Htc: 24%, Plt: 138000/mm3.) Erythrocyte 
sedimentation rate (ESR) was 139 mm/hr and C-
reactive protein (CRP) was 189 mg/L . 
 
Biochemical investigation of the patient’s blood 
revealed AST: 70 U/L , ALT: 123 U/L, ALP: 321 
U/L, GGT: 285 U/L, total protein: 5 g/dL, 
albumin: 2.6 g/dL, globulin: 2.4 g/dL, total 
bilirubin: 1.7 mg/dL, glucose: 159 mg/dL, urea:41 
mg/dL, creatinine: 0.8 mg/dL, uric acid: 2.3 
mg/dL, sodium: 131 mEq/L, potassium: 
3.6mEq/L, iron: 104 µg/dL, total iron binding 
capacity: 127µg/dL, prothrombin time: 16 sec, 
prothrombin activity: 69 %, INR: 1.4, aPTT: 29 
sec. 
 
On a peripheral blood smear, the lymphocytes 
were 97%, monocytes were 3%, no leukocytes, 
eosinophils, basophils, blasts or atypical cells 
were seen. The urine test was 2 positive (++) for 
bilirubin; the sediment contained 5-6 erythrocytes 
per high power field and no bacteria or casts. 
 
Radiographs of the chest were unremarkable. 
Ultrasonography of the abdomen revealed no 
abnormalities. Normal bacterial flora was isolated 
from the throat culture. Urine and blood cultures 
remained sterile. 
 
Serologic tests for hepatitis markers (HbsAg, anti-
HBc IgM, anti-HCV, anti-HAV IgM), anti-HIV, 
anti-HSV 1-2 IgM, anti-CMV IgM, anti-
Parvovirus B19 IgM were all negative. Serologic 
tests for Brucella (STA= standard tube 
agglutination) and monotest were also negative. 
 
Because the patient was febrile and pancytopenic; 
after obtaining specimens of blood, urine and 
throat for culture, intravenous antibiotic therapy 
with ceftazidime (3x2gr) was started. Based upon 
the persistence of fever after 48 hours, amikacin 
(1x1gr) was added to the therapy regimen. At the 
same time, prednisolone 1 mg/kg/day was started. 
In spite of this therapy, the fever persisted (40ºC 
maximally). Thus, ceftazidime plus amikacin 
therapy was switched to meropenem 3x1 gr/day 
IV. On the 10th day, the patient developed sore 
throat and dysphagia suggesting fungal 
esophagitis. Fluconazole 200 mg IV daily was 
started. Total blood count measurement was 
performed daily. Irradiated and filtered platelets 
and erythrocytes were transfused accordingly. No 
underlying immunodeficiency was identified. 
 
The diagnostic procedure was a punch biopsy of 
the skin from the lesions on his lower leg. The 
specimen stained with hematoxylin and eosin was 
examined histopathologically under the light 
microscope. Hyperkeratosis and parakeratosis 
within the epidermis, spongiosis in the spinal 
layer cells and focal vacuolisation within the basal 
cell layer were seen. There was lymphocyte 
infiltration within the papillary dermis. 
Lmphocytes were also seen in the epidermis 
(exocytosis). Taking the clinical findings into 
consideration, the histopathological findings could 
be consistent with grade I-II of acute phase of 
GVHD2. 
 
Bone marrow aspiration and biopsy were 
performed on the 9th hospital day. 
Erythrophagocytosis and hypocellular bone 
marrow with histiocytic reaction characterized by 
loss in the three series were reported. These 
findings could be  consistent with immune system 
diseases, viral infections and the use of some 
drugs (e.g: chloramphenicol, phenylbutazone, 
anticonvulsants, sulfonamides etc.). During 
follow-up, his complete blood count values 
progressively decreased. Despite intensive follow-
up and therapy, the patient died on the 13th 
hospital day (that is nearly five weeks after the 
implicated transfusion). Autopsy was planned but 





Most cellular blood products, including red cell, 
platelet, and granulocyte products, contain viable, 
immunocompetent T lymphocytes 3. When 
transfused into immuno-incompetent recipients, 
these donor lymphocytes may proliferate in the 
patient and lead to the clinical syndrome of TA-
GVHD4,5. TA-GVHD has also been reported in 
immunocompetent patients, especially those who 
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receive transfusions from family members or from 
random donors who share HLA antigens, as is the 
case when the donor is homozygous for an HLA 
haplotype 6,7. In these cases, the recipient does not 
recognize the donor cells as foreign, allowing the 
transfused lymphocytes to proliferate and cause 
TA-GVHD1. 
 
Fever is the most common symptom followed by 
a typical erythematous, maculopapular skin rash 
that begins centrally and spreads peripherally to 
the hands and feet. Abnormalities of hepatic 
function, nausea and bloody diarrhea often occur 
as the process progresses. Leukopenia followed 
by pancytopenia due to marrow failure is quite 
common in TA-GVHD and is seen most often 2 to 
3 weeks after the onset of symptoms. Diagnosis of 
TA-GVHD is difficult, and it is based on the 
clinical picture and can be confirmed 
histologically with a skin biopsy1. 
Immunohistochemical analysis of skin biopsy 
tissue is a useful investigation in pancytopenic 
patients presenting with unexplained rashes. 
 
TA-GVHD is usually rapidly fatal despite 
aggressive treatment. The fatality rate has been 
reported to be greater than 90% 8. Severe systemic 
infections are the most common cause of death, 
which often occurs within 3 to 4 weeks from the 
time of the implicated transfusion. 
 
Corticosteroids, antithymocyte globulin, 
cyclosporine and growth factors have all been 
used with minimal success in the treatment of TA-
GVHD. Because of the lack of effective treatment 
regimens, TA-GVHD should be prevented by 
pretransfusion irradiation of all blood products 
administered to patients at risk. Irradiation inhibits 
proliferation of donor lymphocytes but has no 
significant adverse effect on red cell, platelet, or 
granulocyte function1. 
 
Based primarily on case reports and reviews, a 
number of immunosupressed and 
immunocompetent patient groups can be stratified 
according to risk of developing TA-GVHD 8 
(Table I). Although our patient was presumably 
immunocompetent, because of transfusion from 
blood relatives, he was at high risk of developing 
GVHD according to this categorization. 
 
Since the effective standard therapy of TA-GVHD 
has not been established, the prevention by 
gamma irradiation of cellular blood components is 
most important. All blood products are irradiated 
in the blood banking center in our hospital. But 
the patient had been transfused with blood 
obtained from another blood bank. 
Table I: Risk groups to develop TA-GVHD. 
 
 
In the differential diagnosis, viral infections 
leading to bone marrow suppression, adverse drug 
reactions and hematologic malignancies were 
considered, because the features characterizing 
GVHD may mimic drug reactions or viral 
infection. Some viral infections were excluded as 
the ELISA test results were negative. Examination 
of the bone marrow aspiration and biopsy 
specimen excluded any hematologic malignancy. 
Although the patient had used nonsteroidal anti-
inflammatory drugs for months, repeated 
preoperative total blood counts (before 
transfusion) were within normal limits. Therefore, 
bone marrow suppresion due to drug use was also 
excluded. 
 
Of the possible diagnoses, TA-GVHD would most 
comprehensively explain the clinical picture in 
this patient. 
 
Any unexpected symptoms in a transfusion 
recipient should at least be considered as a 
transfusion reaction and be evaluated. TA-GVHD 
which usually occurs in the setting of an 
High Risk 
Bone marrow transplant (allogeneic & 
autologous) 
Intrauterine transfusions 
HLA-matched platelet transfusions 
Transfusions from blood relatives 
Severe congenital immunodeficiency 
Hodgkin disease 
Moderate rİsk 
Hematologic malignancy (AML, ALL, NHL) 
Patients treated with purine analogue drugs (Eg: 
CLL) 
Malignancies treated with intensive chemo-
/radiotherapy 
Solid organ transplant recipients 
Preterm infants 
Neonates receiving exchange transfusion 
Low / Theoretical Risk 
HIV/ AIDS 
Healthy term neonates 
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immunocompromised recipient receiving 
nonirradiated blood components may also occur in 
immunocompetent recipients. A typical 
presentation includes skin rash, liver function 
abnormalities, and pancytopenia. It is almost 
invariably fatal. Preventive measures include 
exclusion of 1st and 2nd degree relatives as blood 
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